6-month progression is strong survival surrogate in mHSPC
|
Disease progression within 6 months was the strongest surrogate marker for overall survival in patients with metastatic hormone-sensitive prostate cancer treated with combination therapy in a retrospective analysis of the CHAARTED trial. |
Learn more
|